Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people whoโ€™ve been there
  • People who understand what youโ€™re going through
Sign Up Log In
Powered By
Real members of myPHteam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
June 18, 2025
 · 
Reactions
A myPHteam Member

Thanks so much for sharing this Cindy. I start this injection tomorrow. I have been on Opsynvi and attempted to go to the 10/40 from the 10/20 and my side effects were the most of the ones on the less common list. These helped me at rest but no change with activity. So I am glad to hear this. Have you been able to maintain what you gained though you are on hold?
I am trusting that Jesus will carry us through this without side effects. Thanks again for your input. I will be praying your hematocrit comes back up and you feel good again.

June 18, 2025
A myPHteam Member

Yes I am. Yes, hopefully it will be approved for group 2!

September 19, 2025
A myPHteam Member

I am involved in this drug as part of the drug study in Nebraska right now. The only side effect I have is a red mark on my face. It is small. It seems to be working good for me.

June 18, 2025
A myPHteam Member

Good morning Jen, I was on winrevair for 8- 9 months. And it was working wonderful for me! My lung pressure went way down. My heart started looking good again. But my hematocrit and hemoglobin went way down. So my PH Dr put me on hold. Till it goes back up. I have 2 iron infusions and going for my last one today. So maybe I will be able to get back on winrevair. It is a miracle drug. And I did not have any sude effects. God bless! ๐Ÿ™Œ

June 18, 2025
myPHteam

Winrevair (sotatercept) was just approved by the FDA in March 2024 as a new treatment for pulmonary arterial hypertension (PAH). It works differently from other PAH medications by helping to balance cell growth signals in blood vessels, which helps decrease the thickening of pulmonary arteries and improves blood flow to the Show Full Answer

Winrevair (sotatercept) was just approved by the FDA in March 2024 as a new treatment for pulmonary arterial hypertension (PAH). It works differently from other PAH medications by helping to balance cell growth signals in blood vessels, which helps decrease the thickening of pulmonary arteries and improves blood flow to the lungs. When used alongside other PAH therapies, studies show that sotatercept improves blood flow and increases exercise capacity, with patients showing better results in the six-minute walk test. The medication is given as a subcutaneous injection once every three weeks.

Since this is such a new treatment, you may want to discuss with your healthcare team whether it might be appropriate to add to your current treatment plan.

June 18, 2025

Related Questions

View All
A myPHteam Member asked a question ๐Ÿ’ญ
Chambersburg, PA